Discovering an Antibody’s Therapeutic Fingerprint
Understanding an antibody’s mechanism of action (MOA) is critical to its clinical success. Not only does MOA have a large impact on safety and efficacy, but it also influences the intellectual property (IP) and commercial potential of a therapeutic. Those antibodies with novel MOAs represent significant opportunities in the competitive world of pharmaceuticals, and so identifying them is key.
High throughput Surface Plasmon Resonance (SPR) offers a unique advantage in the quest for successful next-generation therapeutic antibodies. Its expanded capabilities compared with traditional SPR and other label-free methods enable comprehensive screening of antibody libraries at the earliest stage of drug discovery, with the additional advantage of high resolution binding characterization through kinetics and epitope binning assays. Combining these results with those from orthogonal studies produces a fingerprint of each antibody’s therapeutic potential.